Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19-Reference-Cited by-同舟云学术

Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19

Published:2023-08-17 Issue:4 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Qiu Ji¹^ORCID,Engelbrektson Anna¹,Song Lusheng¹,Park Jin¹,Murugan Vel¹,Williams Stacy¹,Chung Yunro¹²,Pompa-Mera Ericka Nelly³⁴,Sandoval-Ramirez Jorge Luis⁴,Mata-Marin Jose Antonio⁴,Gaytan-Martinez Jesus⁴,Troiani Eliana⁵,Sanguinetti Maurizio⁵⁶,Roncada Paola⁷,Urbani Andrea⁵⁶,Moretti Giacomo⁶,Torres Javier³^ORCID,LaBaer Joshua¹

Affiliation:

1. Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, USA

2. College of Health Solutions, Arizona State University, Phoenix, Arizona, USA

3. Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

4. Hospital de Infectología, CMN “La Raza”, Instituto Mexicano del Seguro Social, Mexico City, Mexico

5. Università Cattolica del Sacro Cuore, Rome, Italy

6. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

7. Department of Health Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy

Abstract

The clinical presentations of COVID-19 range from asymptomatic to critical illness that may lead to intensive care or even death. The health of the immune system, as partially shaped by past infections or vaccinations, is critical to control and resolve the infection.

Funder

Consejo Nacional de Ciencia y Tecnología

HHS | NIH | National Cancer Institute

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.04690-22

Reference43 articles.

1. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19

2. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

3. Risk factors and predictors associated with the severity of COVID-19 in China: a systematic review, meta-analysis, and meta-regression

4. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

5. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies